Basal-like breast cancers form a distinct subtype of breast cancer characterized by the expression of markers expressed in normal basal/myoepithelial cells. Breast cancers arising in carriers of germline BRCA1 mutations are predominately of basal-like type, suggesting that BRCA1 dysfunction may play a role in the pathogenesis of sporadic basal-like cancers. We analysed 37 sporadic breast cancers expressing the basal marker cytokeratin 5/6, and age-and grade-matched controls, for downregulation of BRCA1. Although BRCA1 promoter methylation was no more common in basal-like cancers (basal 14% vs controls 11%, P ¼ 0.72), BRCA1 messenger RNA expression was twofold lower in basal-like breast cancers compared to matched controls (P ¼ 0.008). ID4, a negative regulator of BRCA1, was expressed at 9.1-fold higher levels in basal-like breast cancer (Po0.0001), suggesting a potential mechanism of BRCA1 downregulation. BRCA1 downregulation correlated with the presence of multiple basal markers, revealing heterogeneity in the basal-like phenotype. Finally, we found that 63% of metaplastic breast cancers, a rare type of basal-like cancers, had BRCA1 methylation, in comparison to 12% of controls (Po0.0001). The high prevalence of BRCA1 dysfunction identified in this study could be exploited in the development of novel approaches to targeted treatment of basal-like breast cancer.
Basal-like breast cancers form a distinct subtype of breast cancer characterized by the expression of markers expressed in normal basal/myoepithelial cells. Breast cancers arising in carriers of germline BRCA1 mutations are predominately of basal-like type, suggesting that BRCA1 dysfunction may play a role in the pathogenesis of sporadic basal-like cancers. We analysed 37 sporadic breast cancers expressing the basal marker cytokeratin 5/6, and age-and grade-matched controls, for downregulation of BRCA1. Although BRCA1 promoter methylation was no more common in basal-like cancers (basal 14% vs controls 11%, P ¼ 0.72), BRCA1 messenger RNA expression was twofold lower in basal-like breast cancers compared to matched controls (P ¼ 0.008). ID4, a negative regulator of BRCA1, was expressed at 9.1-fold higher levels in basal-like breast cancer (Po0.0001), suggesting a potential mechanism of BRCA1 downregulation. BRCA1 downregulation correlated with the presence of multiple basal markers, revealing heterogeneity in the basal-like phenotype. Finally, we found that 63% of metaplastic breast cancers, a rare type of basal-like cancers, had BRCA1 methylation, in comparison to 12% of controls (Po0.0001). The high prevalence of BRCA1 dysfunction identified in this study could be exploited in the development of novel approaches to targeted treatment of basal-like breast cancer. Keywords: BRCA1; basal-like; breast cancer; ID4; metaplastic Basal-like breast cancers form a distinct subtype of breast cancer that can be identified using gene expression microarrays (Perou et al., 2000) , and are characterized by the expression of markers expressed in normal basal/myoepithelial cells (Perou et al., 2000; Nielsen et al., 2004) . Basal-like cancers only infrequently express the oestrogen or progesterone receptor and rarely overexpress HER2 (Nielsen et al., 2004) . Understanding the pathogenesis of this form of breast cancer, and the identification of potential therapeutic targets, is of major importance if the poor prognosis of this subtype is to be improved.
Unlike sporadic cancers, where basal-like cancer represent 15% of invasive cancers (Nielsen et al., 2004; Abd El-Rehim et al., 2005) , 80-90% of cancers arising in BRCA1 germline mutation carriers are of the basallike subtype (Foulkes et al., 2003; Lakhani et al., 2005) . Expression microarray analyses have also indicated strong similarities in gene expression between BRCA1 familial cancers and sporadic basal-like cancers (Sorlie et al., 2003) . This phenotypic overlap has raised the possibility that inactivation of BRCA1 function may also underlie sporadic basal-like cancers, and that loss of BRCA1 function may have an aetiological role in the development of the basal-like phenotype.
A number of previous studies have examined BRCA1 in unselected sporadic breast cancer, identifying both methylation of the BRCA1 promoter in 10-15% of cancers and loss of BRCA1 expression in a number of breast cancers (Catteau et al., 1999; Esteller et al., 2000; Turner et al., 2004) . The incidence of BRCA1 methylation has appeared to be more common in cancers with a high histological grade, and with a triple negative phenotype, suggesting that BRCA1 methylation could underlie basal-like cancers (Magdinier et al., 1998; Catteau et al., 1999; Esteller et al., 2000) . However, recent studies examining the basal-like subtype specifically have generated conflicting results and it is presently unclear whether BRCA1 is dysfunctional in these cancers (Abd El-Rehim et al., 2005; Matros et al., 2005; Richardson et al., 2006) . Here, we examine BRCA1 silencing and downregulation in a large cohort of basal-like cancers with a control non-basal-like population matched for age and grade to eliminate potential confounding factors (Lambie et al., 2003) . In addition, we examined a cohort of metaplastic breast cancers, rare tumours that form a distinct group within the spectrum of basal-like tumours (Reis-Filho et al., 2006) . The Guy's Hospital Tissue Microarray (Gillett et al., 2000) representing 1455 breast cancers was stained by immunohistochemistry for basal cytokeratin 5/6 (Ck5/6) to identify sporadic basal-like cancers (Figure 1a ), and scored as described previously (Simpson et al., 2004) . Ck5/6 expression was present in 7.7% (112/1455) of tumours. Of the Ck5/6 strongly (Score 3) expressing cancers, all of invasive ductal histology, 37 had banked fresh frozen tissue and were selected for further study. These were matched for age and histological grade with 37 control cancers (negative for Ck5/6) of invasive Example cores demonstrating no Ck5/6 expression and strong Ck5/6 expression (original magnification Â 10, with inset Â 40). Crosssection of normal breast duct with positive staining of outer myoepithelial/basal layer, and negative staining of inner -luminal layer (original magnification Â 40). (b) BRCA1 promoter methylation analysis with MSP. Microdissected DNA, prepared as described previously (Simpson et al., 2004) , was modified with sodium bisulphite as described by Herman et al. (1996) and using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA). Primers that do not discriminate between methylated and unmethylated sequence were used to nest PCR amplify bisulphite-treated DNA; forward, 5 0 -TATTTTGAGAGGTTGCTGTTTAG-3 0 and reverse 5 0 -CTAAAAAACCCCACAACCTATCCC-3 0 . The nest-amplified product was diluted 1:50 before subsequent MSP using primers published previously (Esteller et al., 2000) . Controls for all reactions were a negative control with no DNA, unmethylated normal lymphocyte DNA (U Control) and lymphocyte DNA methylated in vitro with the Sss-I methylase (M Control) (NEB, Ipswich, CA, USA). Example PCR run with primers specific for unmethylated (U) and methylated DNA (M). The first four tumours are unmethylated for BRCA1, and last methylated. (c) Incidence of BRCA1 methylation in control cancers (4/37 (11%); 95% confidence interval (CI) 4-25%) and Ck5/6-positive cancers (4/29 cases (14%); 95% CI 4-32%). P ¼ 0.72, Fisher's exact test. Error bars represent binomial 95% CIs. (d) BRCA1 mRNA expression assessed by qPCR normalized for tumour proliferation. Median BRCA1 expression in controls 0.62, median BRCA1 expression in basal-like 0.33, P ¼ 0.008, Mann-Whitney U test. (e) ID4 gene expression assessed by qPCR in control cancers and Ck5/6-expressing basal cancers. Median expression in controls 1.55, and basal-like cancer 13.0,
BRCA1 downregulation in basal breast cancer NC Turner et al ductal histology. Characteristics of the Ck5/6 basal-like cancers are similar to those previously reported for basal-like cancers (Table 1) (Nielsen et al., 2004; Abd ElRehim et al., 2005) .
DNA was prepared from microdissected frozen sections of the Ck5/6 basal-like and control cancers. Of the 37 basal-like cancers, 29 yielded DNA of sufficient quantity for further analysis. We analysed the methylation status of the BRCA1 promoter using methylation-specific polymerase chain reaction (MSP) (Figure 1b ). The incidence of BRCA1 methylation was the same in Ck5/6 basal cancers (14% (4/29)) as control cancers (11% (4/37); P ¼ 0.72) (Figure 1c ). These results were confirmed by bisulphite sequencing in a subset of 10 basal-like cancers (data not shown). Therefore, we found no evidence of increased BRCA1 promoter methylation in sporadic basal-like cancers.
To investigate alternative methods of BRCA1 gene silencing in basal-like cancers, not reflected by promoter methylation, we analysed BRCA1 messenger RNA (mRNA) expression. RNA was prepared from microdissected frozen sections of 20 Ck5/6 basal and 20 control cancers. Expression of BRCA1 mRNA assessed using quantitative real-time reverse transcription-PCR (qPCR), and normalized for the expression of Cyclin B1 (Staff et al., 2003) to control for the cell cycle regulated expression of BRCA1; BRCA1 is expressed in S-and G2/M-phase cells but not in G 0 /G 1 (Ruffner and Verma, 1997) . Median BRCA1 expression was significantly lower in basal-like cancers (median expression 0.33, interquartile range 0.21-0.43) than in controls (0.62, 0.44-0.75; P ¼ 0.008) (Figure 1d ), reflecting downregulation of the BRCA1 transcript in basal-like cancers. Similar results were obtained normalizing BRCA1 expression for mitotic count (median expression in basal-like 0.51 (0.26-0.91), expression in controls 1.00 (0.62-1.9); P ¼ 0.019). As expected, BRCA1-methylated cancers expressed a lower level of BRCA1 mRNA (0.18, 0.13-0.35) than non-methylated cancers (0.46, 0.32-0.74; P ¼ 0.017, Mann-Whitney U test), confirming the validity of the methylation analyses. We examined BRCA1 expression by immunohistochemistry in the Ck5/6-positive cancers and controls. There was a positive correlation between BRCA1 expression by qPCR and BRCA1 staining (Spearman correlation coefficient r ¼ 0.50, P ¼ 0.0051) (Supplementary Figure  1) . However, not all tumours with high BRCA1 staining had high BRCA1 qPCR, highlighting the problems with BRCA1 immunohistochemistry as reported previously (Perez-Valles et al., 2001) (Supplementary Figure 1) .
Breast metaplastic carcinomas encompass a highly heterogeneous group of neoplasms characterized by an admixture of adenocarcinoma with areas of spindle, squamous, chondroid or osseous differentiation (Huvos et al., 1973) . In previous studies, we and others have demonstrated that these tumours may be seen as part of the spectrum of basal-like carcinomas (Reis-Filho et al., Table 1) . Eighty-eight per cent (23/26) would be classified as basal-like breast carcinomas using established criteria (Nielsen et al., 2004) . The methylation status of the BRCA1 promoter was assessed using MSP (Figure 2) . DNA was of sufficient quality to assess methylation status in 27 cases. There was a high incidence of BRCA1 methylation in metaplastic cancers (63% (17/27); 95% confidence interval 42-81%). MSP can be problematic with DNA extracted from FFPE sections. Therefore, to confirm these results, bisulphite-treated DNA was separately amplified for bisulphite sequencing of the BRCA1 promoter (Figure 2 ). Bisulphite sequencing concurred with MSP in 16/18 samples (Supplementary Table 1), confirming the high incidence of BRCA1 methylation. The two discordant cases were positive only by MSP reflecting the greater sensitivity of the technique for infrequent promoter methylation. In common with familial BRCA1 cancers, where TP53 mutation is selected in cancers that have lost BRCA1 function (Crook et al., 1998) , P53 overexpression was common in this series of metaplastic cancers (64% (18/ 28) of cases).
We sought to understand the mechanism for relative but incomplete silencing of BRCA1 expression in basallike cancers. ID4 has previously been shown to be a negative regulator of the BRCA1 promoter (Beger et al., 2001) . We found that ID4 expression was 9.1-fold higher in basal-like cancers (13.5, 2.6-34.6) than in controls (1.48, 0.86-2.11; Po0.0001) ( Table 2 ). High ID4 expression was restricted to the basal-like cancers (Figure 1e ). Our finding of overexpression of ID4 in basal-like cancers may, therefore, provide an explanation for BRCA1 downregulation in this subtype.
We investigated the expression of additional genes in BRCA1-associated pathways by qPCR. There was no statistically significant difference in expression of BARD1, BRIP1 or BRCA2, between basal-like cancers and controls after normalization for tumour proliferation rates (Table 2) , or without normalization for proliferation (data not shown). However, we found that BARD1 expression correlated highly with BRCA1 expression (Spearman correlation coefficient r ¼ 0.65, Po0.0001), suggesting a functional significance in the variation of BRCA1 expression. This concurs with Ck, cytokeratin. Gene expression assessed by real-time RT-PCR in control cancers and Ck5/6-expressing basal cancers. Median expression and interquartile range of BRCA1, BARD1 (BRCA1-associated RING domain 1), BRIP1 (BRCA1-interacting protein C-terminal helicase 1), BRCA2, ID4 (Inhibitor of DNA binding 4), XIST (X (inactive)-specific transcript), KRT5 (Keratin 5, Ck5), SFN (Stratifin, Sigma 14-3-3) (Simpson et al., 2004) . n -number of tumours. Mann-Whitney U test for comparisons. RNA was prepared from microdissected frozen sections using PicoPure RNA isolation Kit (Arcturus, Mountain View, CA, USA). cDNA was synthesized using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen). Real-time qPCR was performed on the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster city, CA, USA) with Assay-on-Demand primer/probe sets (Applied Biosystems), details of which are available on request. Gene expression was calculated relative to expression of two endogenous control genes, b-glucuronidase multiplex with gene primers and 18S rRNA. Baseline expression was gene expression in the BT474 cell line (ATCC, Manassas, VA, USA). BRCA1 expression, after adjusting to endogenous controls, was normalized for tumour proliferation by dividing the BRCA1 expression level by CCNB1 expression. The BARD1, BRIP1 and BRCA2 expression data displayed are also normalized for tumour proliferation. Bold typeface -statistically significant.
previous evidence that expression of these genes is coregulated (Joukov et al., 2001) as well as being subject to regulation by co-degradation (Fabbro et al., 2002) . In keeping with the recent demonstration of loss of X inactivation in basal-like cancers (Richardson et al., 2006) , we found expression of XIST (X inactive specific transcript) RNA to be twofold lower in basal-like cancers (Table 2 ). BRCA1 has previously been shown to support X chromosome inactivation (Ganesan et al., 2002) . XIST is expressed from the inactive X chromosome and cancer cell lines with loss of X chromosome inactivation have frequently lost XIST expression (Sirchia et al., 2005) . Loss of XIST expression may therefore be a surrogate for loss of BRCA1 function. The expression of both basal cytokeratins Ck5/6 and Ck14 is especially common in BRCA1 familial cancers (Lakhani et al., 2005) . We compared gene expression in cancers expressing neither basal cytokeratin, cancers that expressed Ck5/6 only and cancers that expressed both Ck5/6 and Ck14. Across these three groups, the expression of BRCA1 and XIST progressively decreased. In contrast, ID4 expression was 15.4-fold higher in Ck5/6-and Ck14-positive basal-like cancers than cytokeratin-negative controls (Table 3) . BRCA1 expression was significantly lower in cancers with pushing borders (P ¼ 0.020) and cancers with central necrosis (P ¼ 0.023) (Data not shown), features that are known to correlate with a basal-like phenotype (Livasy et al., 2006) . Cancers that expressed Ck5/6, had pushing borders, and central necrosis expressed very low BRCA1 expression (0.25, 0.19-0.37) in comparison to those that expressed none of these features (0.70, 0.51-0.86, P ¼ 0.0095).
We hypothesized that the phenotypic overlap of BRCA1 familial cancers and sporadic basal-like cancers (Foulkes et al., 2003; Sorlie et al., 2003; Lakhani et al., 2005) implied that sporadic basal-like cancers might have an underlying defect in BRCA1-related pathways (Turner et al., 2004) . Recent studies examining the basal-like subtype have generated conflicting results. Two papers have reported reduced BRCA1 expression, assessed by immunohistochemistry, in basal-like cancers (Abd El-Rehim et al., 2005; Ribeiro-Silva et al., 2005) . Another reported that BRCA1 expression and nuclear focus formation was retained in basal-like cancers (Richardson et al., 2006) . One further study found no association of BRCA1 methylation with the basal-like subgroup with a small number of basal-like cancers (Matros et al., 2005) .
Our results have revealed a complex pattern of BRCA1 dysregulation in basal-like cancers. We found very frequent methylation-induced BRCA1 silencing in metaplastic tumours. However, in unselected basal-like cancers, BRCA1 methylation was no more common than matched controls. Despite this, BRCA1 expression is downregulated in basal-like cancers with significantly lower BRCA1 expression levels. Cancers with many basal-like features expressed the lowest level of BRCA1. This suggests that there is substantial heterogeneity in the basal-like subtype, where cancers with a less complete phenotype have less frequent BRCA1 downregulation. Interestingly, metaplastic cancers express many of the basal-like markers examined, epidermal growth factor receptor, Ck5/6 and Ck14 (Supplementary Table 1) .
A potential cause of BRCA1 downregulation is revealed by the finding of high ID4 expression only in basal-like cancers, with low expression in all control cancers in keeping with the recent finding of ID4 methylation in breast cancers (Umetani et al., 2005) . ID4 has previously been shown to be a negative regulator of the BRCA1 promoter (Beger et al., 2001) , with overexpression of exogenous ID4 suppressing BRCA1 expression (Beger et al., 2001) . ID family proteins are known to be key regulatory proteins in developmental processes, acting through negative regulation of gene transcription to block cell differentiation (Perk et al., 2005) . Recent data have also linked BRCA1 to control of differentiation in a model of breast duct development (Furuta et al., 2005) . These data support the suggestion that the ID4/BRCA1 axis could play a role in early breast epithelial biology and differentiation (Foulkes, 2004) . It is important to note that our study is observational and cannot delineate if BRCA1 downregulation has a causative role in basallike tumorigenesis, or is a consequence of the basal-like phenotype.
Cells deficient in BRCA1 function have a defect in DNA double-strand break (DSB) repair that renders them particularly sensitive to chemotherapy drugs that generate DNA DSB (Turner et al., 2004) , and highly sensitive to chemical inhibitors of the poly (ADP-ribose) polymerase enzyme (Brody, 2005; Farmer et al., 2005) . Our findings raise the possibility that these approaches targeting BRCA1 dysfunction may be useful in the treatment of basal-like cancers. The complexity in downregulation of BRCA1 expression revealed in this study suggests that these approaches may only be 2.0 (1.1-2.5) 4.7 (3.0-5.6) 5.7 (4.0-7.9) o0.0001
Ck, cytokeratin. Gene expression analysis in cancers expressing both Ck5/6 and Ck14, Ck5/6 only, and controls expressing neither basal Ck. Median expression and interquartile range. Kruskal-Wallis test for comparison between three groups. n -number of tumours. Bold typefacestatistically significant.
effective in the treatment of a subset of basal-like cancers. Identification of specific markers for these cancers will be essential if we are to translate an understanding of BRCA1 function into targeted treatments for this poor prognosis subtype.
